Financings in Brief: Avitar
This article was originally published in The Gray Sheet
Executive Summary
Avitar: Registration statement filed with the Securities and Exchange Commission for the offering of 13 mil. shares (including 12.7 mil. by the company and 361,000 by selling shareholders) has been declared effective, the firm states. The shares offered by the company would be issued if "redeemable warrants and certain other warrants were exercised." If all warrants were exercised, the aggregate exercise price would be about $21.6 mil. the firm states. "Proceeds, if any, will be used to continue to expand the business" and for "general working capital purposes," Avitar says...
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.